Solu Therapeutics is a precision-medicine company developing therapeutics to eliminate disease-driving cells.

Solu Therapeutics, founded by Longwood Fund, is a precision-medicine company developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates, licensed from GSK, unlocks antibody-intractable cell surface targets providing the capability to develop next generation medicines that harness the power of biologics with the vast target binding space of small molecules. Unique characteristics of CyTaC platform molecules include: (i) unlocking new tumor-associated antigens to eliminate cancer cells, (ii) depleting pathogenic immune cells, and (iii) extending the half-life of small molecule antagonists and agonists.

Our Team

Management

Phil Vickers, PhD

President and Chief Executive Officer

Phil Vickers, PhD

President and Chief Executive Officer


Dr. Phil Vickers is President and Chief Executive Officer at Solu Therapeutics.  With over 30 years of experience in the biopharma industry, Dr. Vickers brings a wealth of knowledge and experience to the Solu team.  His career includes R&D leadership roles of increasing responsibility at Merck Research Laboratories, Pfizer, Boehringer-Ingelheim and Shire Pharmaceuticals, where he was Global Head of R&D and a member of the Executive Leadership Team.  In addition to leading roles in major pharmaceutical companies, Dr. Vickers was also Chief Executive Officer at Northern Biologics and Faze Medicines.  His experiences span the development of both small molecules and biologics for common indications and rare diseases, and across multiple therapeutic areas – including oncology, immunology and inflammation, cardiovascular disease, and neurodegeneration.  Dr. Vickers has a Ph.D. in Biochemistry from the University of Toronto, and prior to joining Merck he undertook postdoctoral studies at the National Cancer Institute in Bethesda, Maryland.

Brandon Turunen, PhD

Co-founder and Chief Technology Officer

Brandon Turunen, PhD

Co-founder and Chief Technology Officer


Dr. Brandon Turunen is co-founder, Chief Technology Officer, and Head of Drug Discovery at Solu Therapeutics.  Dr. Turunen brings over 15 years of drug discovery experience including oncology, immunology, and chemical biology leadership roles.  He most recently was the head of Chemical Biology at GSK where he led a diverse team of chemists, biologists, and immunologists focused on developing platforms to translate human genetic insights into drug discovery programs.  Also, while at GSK, he was the head of the Synthetic Immunology Discovery Performance Unit which developed new synthetic constructs to create and control human immunity.  In addition to these roles Dr. Turunen built a global chemical proteomics group/platform, led oncology/IO programs, and worked in the Office of the CEO to develop a commercial strategy to increase access to medicines.

His scientific contributions are reflected in his publication/patent record, and he has played key roles in new technology due diligence leading to both company and asset acquisitions as well as newco creation.  He is the recipient of numerous awards including the ACS mid-career award (2023) and the GSK Beautiful Biology award.  Dr. Turunen has formal training in organic/medicinal chemistry and holds a B.S. from Michigan State University, a Ph.D. from the University of Kansas (Gunda Georg) and conducted post-doctoral training at Stanford University (Barry Trost).

Ewelina Morawa, MD

Chief Medical Officer

Ewelina Morawa, MD

Chief Medical Officer


Dr. Ewelina Morawa is an oncologist and a stem cell transplantation physician who has been in the pharmaceutical/biotech industry for the past 10 years and serves as a part time CMO for Solu Therapeutics. Dr. Morawa has led oncology, cell and gene therapy programs through different stages of development including IND filings, first-in-human and registrational trials. Most recently she was the VP of clinical development at CRISPR Therapeutics leading the CD19 and BCMA allogeneic CAR T programs. While there she also initiated clinical programs with allogeneic CAR T for CD70 in renal cell carcinoma and T cell lymphoma as well as first in human trial with CRISPR gene therapy in thalassemia and sickle cell disease with exagamglogene autotemcel (exa-cel) (now with Vertex).

Prior to joining CRISPR she held roles of increasing responsibility in clinical development at AbbVie and at Novartis. At Novartis, she led the first, multi-site, registrational autologous CAR T trials in US in pediatric ALL and DLBCL which resulted in the approval of Kymriah® (tisagenlecleucel-t).

Dr. Morawa received her hematology/oncology training at Weill Cornell Medical College/New York Presbyterian Hospital and additional stem cell transplantation training at Memorial Sloan Kettering Cancer Center.

Craig Leach, PhD

VP, Head of Biology

Craig Leach, PhD

VP, Head of Biology


Dr. Craig Leach is Vice President, Head of Biology and co-inventor at Solu Therapeutics. Dr. Leach has over 15 years of experience in leading early stage drug discovery programs at small biotech and large pharmaceutical companies.  He co-developed and taught a course on Drug Discovery and Development at PENN with Dr. Ben Black.

Following his studies at the University of Virginia, Dr. Leach conducted his post-doctoral research at Harvard University where he studied the roles of ubiquitylation and SUMOylation in the DNA damage response.  This research led to him joining Progenra Inc to lead internal and external drug discovery programs identifying modulators of the ubiquitin pathway for the treatment of various diseases including cancer, inflammation, and infectious disease.  Dr. Leach joined GSK in 2012 where he continued to lead projects across therapy areas including oncology and immunology.  While at GSK he co-invented the CyTAC platform to unlock intractable extracellular targets.

Dr. Leach holds a B.S. in Biology from Eastern Nazarene College and a Ph.D. in Microbiology from the University of Virginia.  He currently serves on the Scientific Advisory Board of AVMBioMed.

Ron Swearingen, MS, PMP

VP, Program Management

Ron Swearingen, MS, PMP

VP, Program Management


Mr. Ron Swearingen is the Vice President of Program Management and brings over two decades of portfolio, program, and asset leadership to Solu Therapeutics. He has contributed to ten commercial products both as a scientist and as a program lead responsible for growing rare disease assets.

At Translate Bio, he played a key role in restructuring the company post the acquisition of an mRNA platform from Shire.  He also shaped corporate strategy and led the Sanofi Pasteur collaboration as co-chair of the JSC while providing overall internal program leadership. During that time, he implemented various operating models and led numerous teams to help drive five assets into the clinic in four years. Translate Bio was acquired by Sanofi Pasteur in 2021.

Mr. Swearingen also spent five years at Shire contributing to the growth of the $2B rare disease portfolio, serving as the first program manager for the Fabry/Gaucher franchise team ($600M in revenue) and in strategic product management for the MPS and Angioedema franchise ($1B in revenue). While at Aegerion Pharmaceuticals, he co-led their first portfolio reprioritization to support the organization’s growth from a single asset to one with multiple investment options. Mr. Swearingen has successfully established portfolio and program management functions for several start up organizations and early in his career served as a staff scientist at GelTex Pharmaceuticals (acquired by Genzyme for $1B).

Mr. Swearingen received his B.S. in Chemistry from West Virginia University, his M.S. in Analytical Chemistry from the University of Massachusetts, Lowell and is a Project Management Professional (PMP®). He also holds an Executive Certificate in Management and Leadership from MIT.

John Pribis, PhD

Co-founder, Head of BD, Strategy, and non-R&D Operations

John Pribis, PhD

Co-founder, Head of BD, Strategy, and non-R&D Operations


Dr. John Pribis is co-founder and Head of BD, Strategy, and non-R&D Operations at Solu Therapeutics.  Before joining Solu Therapeutics, he worked on the investment and venture creation team at Longwood Fund, where he was involved in investing, ideating, building, and supporting portfolio companies.  Dr. Pribis was the founding VP of Strategy and Operations at Solu Therapeutics and DEM BioPharma.  Previously, John was a co-founder of Apriori Bio and he worked in venture and company creation at Flagship Pioneering, working across the portfolio company life cycle.

Dr. Pribis also worked in drug discovery and development in immunology focused therapeutic areas at University of Pittsburgh in a translational drug development project. He led teams that discovered and developed small molecules that inhibit pathogenic inflammatory signaling, including one that progressed to clinical trials. Dr. Pribis earned his Ph.D. in Genetics and Microbiology at Baylor College of Medicine. He studied genetics, immunology, and drug resistance and discovered several drugs that inhibit the evolution of bacterial antibiotic resistance.  Dr. Pribis received several awards for his work, including the Nat L. Sternberg Thesis prize from Cold Spring Harbor Labs and the Deborah K. Martin Achievement award in biomedical research.  He has published more than 20 peer-reviewed publications, including in top-tier journals.  His work has been cited more than 1500 times and featured in several outlets, including CNN and BBC Radio 4.  Dr. Pribis also completed post-baccalaureate work in computer science and received his B.S. in biosciences from Drexel University.

Kelly Honohan

General Counsel and Company Secretary

Kelly Honohan

General Counsel and Company Secretary


Kelly Honohan is the General Counsel and Company Secretary at Solu Therapeutics. Previously, Kelly established her own legal practice advising biotech and pharmaceutical companies and, in that capacity, served as a consultant General Counsel and Company Secretary for Faze Medicines, Inc. and Northern Biologics, Inc.. She held increasingly senior leadership roles at Shire Plc (now Takeda Pharmaceuticals), including serving as Vice President & Senior Legal Counsel, where she provided global legal support for commercial and development programs within Shire’s rare disease portfolio. Kelly also served as in-house counsel at Bristol-Myers Squibb Company with responsibility in the company’s U.S. Medicines group, and then as the lead attorney for its Medical Imaging business. Kelly began her private practice as an associate in the corporate department of Ropes & Gray, LLP.

Directors and Observers

Christoph Westphal, MD, PhD

Co-founder and Executive Chairman, Solu Tx
Founding Partner, Longwood Fund

Christoph Westphal, MD, PhD

Co-founder and Executive Chairman, Solu Tx
Founding Partner, Longwood Fund


Dr. Westphal is co-founder and General Partner of Longwood Fund and has spent over 20 years as a biotech CEO, entrepreneur, and investor. Dr. Westphal has been the co-founder, CEO, and lead investor of seven biotechnology companies that have completed initial public offerings (IPOs) and created sustained market value of over $45 billion and have developed and received FDA approval for over 10 important drugs. These include: Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, acquired by J&J in 2020), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Acceleron Pharma, Inc. (NASDAQ: XLRN, acquired by Merck in 2021), Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT, acquired by GSK in 2008), Verastem (NASDAQ: VSTM), and TScan Therapeutics (NASDAQ: TCRX).

Dr. Westphal was also co-founder of Alnara Pharmaceuticals (acquired by Eli Lilly in 2010); co-founder/CEO of DEM Bio Pharma; co-founder/CEO of Immunitas Therapeutics; co-founder/Chair of Solu Therapeutics; co-founder of Tome Biosciences; co-founder of Pyxis Oncology (NASDAQ: PYXS); and co-founder of Concert Pharmaceuticals (NASDAQ: CNCE, acquired by Sun Pharma in 2023).

Companies founded by Dr. Westphal have created thousands of jobs in the Boston area.

Dr. Westphal and Longwood partners have founded over 20 biotech companies, received FDA approval for over 20 important drugs, including the first RNAi therapy; for currently incurable cancers; the largest-selling heparin in the United States; a therapy for MS; for Beta Thalassemia and Myelodysplastic Syndrome; and several experimental medicines: for cystic fibrosis (phase 3); for serious inflammatory disorders (phase 2), and created sustained market caps of over $100 billion.

Dr. Westphal earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University; and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal has served or currently serves as a member or director of: the Boston Commercial Club, the Biotechnology Industry Organization’s (BIO) Emerging Companies Section Governing Board, the Board of Fellows of Harvard Medical School, and the Board of Trustees of the Boston Symphony Orchestra; he is also a member of the ownership group of the Boston Celtics. Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in journals such as Cell, Nature, and Nature Genetics. Dr. Westphal has been featured on 60 Minutes with Morley Safer, CNN’s Vital Signs with Dr. Sanjay Gupta, an ABC News Special hosted by Barbara Walters, and as the subject of Fortune, New York Times, and Wall Street Journal cover articles. Dr. Westphal has generally avoided media interviews since 2010.

Omar Khalil, MSE

Director, Solu Tx
Partner, Santé Ventures

Omar Khalil, MSE

Director, Solu Tx
Partner, Santé Ventures


Mr. Omar H. Khalil manages Santé’s Boston Office and concentrates on biotechnology, where he partners with scientific founders and entrepreneurs across multiple therapeutic areas and modalities. Mr. Khalil joined Santé in 2007 and rejoined in 2020 after holding various transactional and operational leadership roles within the pharmaceutical and biotech industry. He held senior leadership roles with Baxter International, Baxalta (now part of Takeda), and Kaléo, a commercial-stage biotech. In these positions, he led and managed businesses ranging from early clinical development to commercial launch, which scaled to more than $3 Billion in annual sales. Earlier in his career, he worked at McKinsey & Company in the healthcare practice, advising leading pharmaceutical and medical device companies on growth and M&A strategies. Mr. Khalil serves as a board member, advisor, and mentor to several organizations focused on biotech entrepreneurship and is a member of the Leadership Advisory Board at the University of Michigan College of Engineering. He received his M.SE and B.SE in Biomedical Engineering summa cum laude from the University of Michigan with a concentration in Tissue Engineering.

John Hamer, PhD

Director, Solu Tx
Managing Partner, DCVC Bio

John Hamer, PhD

Director, Solu Tx
Managing Partner, DCVC Bio


Prior to co-founding DCVC Bio, Dr. John Hamer was a VP at Monsanto and Managing Director of Monsanto Growth Ventures (MGV). Before joining MGV, Dr. Hamer was a Managing Director at Burrill & Company. Prior to his career in venture capital, Dr. Hamer was an entre­pre­neur, initially at Paradigm Genetics, where he joined as a visiting scientist before becoming Chief Science Officer and eventually President and CEO following the company’s IPO. After Paradigm, he founded and served as CEO of Arête Ther­a­peu­tics, which earned backing from leading life science venture firms.

Dr. Hamer started his career in academia, rising to the rank of Full Professor in the Department of Biological Sciences at Purdue University, where he was a David and Lucille Packard Fellow and an NSF Pres­i­den­tial Faculty Fellow. Dr. Hamer received a B.Sc. and an M.Sc. from the University of Windsor and a Ph.D. in Micro­bi­ology from the University of California, Davis.

Satoshi Konagai, MBA, MSc

Director, Solu Tx
Senior Investment Manager, Astellas Venture Management

Satoshi Konagai, MBA, MSc

Director, Solu Tx
Senior Investment Manager, Astellas Venture Management


Mr. Satoshi Konagai joined Astellas Venture Management (AVM) in 2020. Before joining AVM, he worked at the Strategic department at Astellas Pharma Inc. based in Tokyo HQ since 2015. He has led various internal projects and evaluation of external later stage opportunities across multiple therapeutic areas and modalities including Oncology, Ophthalmology and regenerative medicine. In parallel, he served as a member who develops corporate global R&D strategy and business strategy for regenerative medicine using his scientific and business intelligence. From 2004 to 2015, he was engaged in Oncology research programs including kinase inhibitors, Immuno-Oncology and biologics from target discovery to clinical stage as a pharmacology research scientist in Drug Discovery Research Center at Astellas Pharma Inc. Mr. Konagai has received his Master of Life Science degree in the field of Integrated Life Science from Kyoto University and Master of Business Administration, Entrepreneurship and Innovation from University of Massachusetts Lowell.

Peter Hutt, JD

Director, Solu Tx
Senior Counsel, Covington & Burling LLP

Peter Hutt

Director, Solu Tx
Senior Counsel, Covington & Burling LLP


Mr. Peter Barton Hutt is a Senior Counsel in the Washington, DC law firm of Covington & Burling LLP, specializing in Food and Drug Law.  He began his law practice with the firm in 1960 and, except for his four years in the government, has continued at the Firm ever since. He was named by The Washingtonian magazine as one of Washington’s 50 best lawyers (out of more than 40,000) and as one of Washington’s 100 most influential people. He is fully engaged in providing advice to clients on all aspects of FDA regulation.

Since 1994, he has taught a full course on Food and Drug Law during Winter Term at Harvard Law School. He is the lead co-author of five editions of Food and Drug Law: Cases and Materials (Foundation Press). From 1971 to 1975 Mr. Hutt was Chief Counsel for the Food and Drug Administration.  During his tenure as FDA Chief Counsel, Mr. Hutt led the transformation of the agency from outdated law enforcement to modern administrative law. Mr. Hutt has been referred to as the Dean of Washington Food and Drug Bar and as the Father of Modern Food and Drug Law.

Mr. Hutt has been a member of the National Academy of Medicine (formerly called the Institute of Medicine (IOM)) of the National Academies of Science, Engineering, and Medicine (NASEM) since the IOM was formed in 1971. He has served on a wide variety of other academic and scientific Advisory Boards and on the Board of Directors for more than 30 healthcare biotechnology companies. Mr. Hutt has also been a member of several biotechnology company advisory boards.

Casey Cunningham, MD

Observer, Solu Tx
Partner and CSO, Santé Ventures

Casey Cunningham, MD

Observer, Solu Tx
Partner and CSO, Santé Ventures


Dr. Casey Cunningham, MD is a Partner and Chief Scientific Officer of Santé Ventures. Before joining Santé, Dr. Cunningham had a long academic career, first as a faculty member at Harvard Medical School and then as the Associate Director of the Mary Crowley Cancer Research Center, an early phase clinical trial institute with an emphasis on gene and cell-based therapies.

In addition to serving as Director for multiple Santé portfolio companies, Dr. Cunningham has played operating roles acting as Chief Medical Officer for Molecular Templates, Terapio and Iterion Therapeutics.

He serves on numerous Advisory Boards, including MD Anderson, The City of Hope, and Baylor Medical School. Dr. Cunningham is also on the National Board of the Leukemia and Lymphoma Society, where he chairs the Therapy Acceleration Program.

Dr. Cunningham attended fellowship training in oncology and hematology at Massachusetts General Hospital after an internal medicine residency at the Medical College of Wisconsin, where he was also Chief Medical Resident. He earned his M.D. from the University of Texas Southwestern Medical School and his B.S. in physics and biology from Texas A&M.

Scientific Advisory Board and Advisors

David Donabedian, PhD

Co-founder & Sr. Advisor
Executive Partner, Interim NewCo CEO, Longwood Fund

David Donabedian, PhD

Co-founder & Sr. Advisor
Executive Partner, Interim NewCo CEO, Longwood Fund


Dr. David H. Donabedian is an Executive Partner at Longwood Fund. He joined the fund in 2015 as a Venture Partner and has over 20 years of professional experience and expertise leading business development, venture teams and demonstrated track record of company creation. He is founding CEO of Solu Therapeutics, co-founder and start-up CEO of DEM BioPharma, start-up CEO of ImmuneID, founding CEO of Axial Therapeutics and founding executive of Alcyone Therapeutics.

Prior to joining Longwood, Dr. Donabedian held various leadership roles at biopharmaceutical companies including AbbVie (NASDAQ: ABBV) and GlaxoSmithKline (NYSE: GSK). At AbbVie he served as Vice President and Global Head of Ventures and Early-Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President of Global New Deal Strategy and Development at GlaxoSmithKline, VP of Business Development, Surface Logix, (sold to Kadmon, acquired by Sanofi, for $1.9B) and Senior Manager at Accenture’s Strategic Services Consulting Group.

Dr. Donabedian holds a B.A. in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Anuncia Inc. and Alcyone Therapeutics, Inc.

Kipp Weiskopf, MD, PhD

Co-founder and Co-chair of SAB

Kipp Weiskopf, MD, PhD

Co-founder and Co-chair of SAB


Dr. Kipp Weiskopf is a Valhalla Fellow at Whitehead Institute for Biomedical Research. He is a leader in the fields of antibody discovery and innate immunotherapy. He oversees a research laboratory that studies novel immune checkpoints in cancer and other life-threatening diseases. Dr. Weiskopf is concurrently appointed as a physician at Dana-Farber Cancer Institute. He previously earned his medical and graduate degrees at Stanford University. As a member of Dr. Irving Weissman’s laboratory, he characterized the CD47/SIRPa interaction as an immune checkpoint that regulates macrophages in cancer. He engineered therapies that stimulate macrophages to attack tumors and showed these could be effective for both solid and hematologic malignancies.

Dr. Weiskopf is an inventor on 20 issued U.S. patents pertaining to macrophage-directed therapies. He generated foundational technology for the company Forty Seven (acquired by Gilead), and he has co-founded three additional companies that are pursuing drug discovery and development in oncology: ALX Oncology, DEM Biopharma, and Solu Therapeutics. Therapies that Dr. Weiskopf invented are currently under investigation in Phase 1 and Phase 2/3 clinical trials for patients with cancer.

Dr. Weiskopf completed his medical residency at Brigham and Women’s Hospital and is board certified in Internal Medicine. He has been awarded a Winston Churchill Scholarship, the Harold M. Weintraub Graduate Student Award, first place in the Collegiate Inventors Competition, an ASCO Young Investigator Award, a Department of Defense Career Development Award, the inaugural AACR-AstraZeneca Career Development Award for Physician-Scientists in Honor of José Baselga, and a Research Project Grant (R01) from the National Cancer Institute. Dr. Weiskopf previously earned a B.A. summa cum laude from Amherst College and an M.Phil. in Genetics from University of Cambridge.

Kai Wucherpfennig, MD, PhD

Founding SAB member

Kai Wucherpfennig, MD, PhD

Founding SAB member


Dr. Kai Wucherpfennig is Professor and Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. His research focuses on the discovery of genes that control the activity of cytotoxic T cells in the tumor microenvironment drawing insights for the development of next-generation cancer immunotherapies. He has received a number of honors and awards, including his election as a Fellow in the American Society for the Advancement of Science, his election as a member of the Henry Kunkel Society at Rockefeller University, and his election as a member of the American Society for Clinical Investigation. Dr. Wucherpfennig serves as an advisor to a number of immuno-oncology companies and venture funds.

Stephen Hodi, MD

SAB member

Stephen Hodi, MD

SAB member


Dr. F. Stephen Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, the Sharon Crowley Martin Chair in Melanoma at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.  Dr. Hodi is a graduate of Harvard University and Cornell University Medical College.  He completed his postdoctoral training in In­ternal Medicine at the Hospital of the University of Pennsylvania and his medical oncology training at Dana-Farber cancer Institute, where he joined the faculty in 1998.

His research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma.  Dr. Hodi is a member of the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the American Association for Cancer Research, the Eastern Cooperative Oncology Group Melanoma Committee, the Society for Immunotherapy of Cancer, the European Academy of Tumor Immunology and a founding member of the Society for Melanoma Research.

Dr. Hodi is an internationally recognized leader in the development of immune therapy and melanoma therapeutics. In particular, he is known for the clinical development of immune checkpoint inhibitors.  His clinical investigation efforts have pioneered the use of immune checkpoint blockade and combinatorial approaches to treat cancer.  His publications include articles in the Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and the New England Journal of Medicine.

Allen Oliff, MD

SAB member

Allen Oliff, MD

SAB member


Dr. Allen Oliff graduated cum laude from Brandeis University in 1971 and attended the Albert Einstein College of Medicine in New York City until 1974. Thereafter, he completed his training in internal medicine at the Bronx Municipal Hospital Center in New York and obtained fellowship training in medical oncology in the Clinical Oncology Program of the National Cancer Institute at the National Institutes of Health in Bethesda, Maryland. In 1985, Dr. Oliff was recruited to the Merck Research Laboratories in Pennsylvania as the Director and Head of Cancer Research. In 1991, he was appointed to the position of Executive Director of Cancer Research at Merck and Co.

Throughout his career Dr. Oliff has pursued investigations into the molecular pathogenesis of cancer. These studies focused on RNA tumor viruses, oncogenes and tumor suppressor genes. Dr. Oliff has authored over 120 peer reviewed publications in these fields, has been an invited speaker at numerous national and international meetings on these topics and member of multiple related societies and editorial boards. He has received the Louise and Allston Boyer Award for Cancer Research from Memorial Sloan Kettering Cancer Center and a Scholar Award from the Leukemia Society of America. Dr. Oliff has served as a member of the Board of Scientific Counselors of the NCI and is an adjunct professor of pharmacology at the Thomas Jefferson University College of Medicine.

After serving as Senior Vice President of Drug Discovery at DuPont Pharmaceuticals, in 2001 Dr. Oliff joined GlaxoSmithKline as Senior Vice President and Head of the Center of Excellence for Drug Discovery. In July of 2006, he was appointed head of the newly created Molecular Discovery Research Department at GSK.

In May of 2006, Dr. Oliff established the Virtual Proof of Concept (VPoC) DPU. As head of VPoC, his mission with his team has been to bring novel medicines to C2MD decisions more quickly and at a lower cost.

During his career at GSK, Dr. Oliff has been responsible for the creation of seven marketed products (Tykerb, Votrient, Arranon, Promacta, Altabax, Mekinsit and Tafinlar) and for two other agents currently in late-stage development. These drugs are used in the treatment of various forms of cancer, thrombocytopenia, skin infections and anemia due to renal disease.

Gary Gordon, MD, PhD

Clinical Advisor

Gary Gordon, MD, PhD

Clinical Advisor


Dr. Gary Gordon, MD, PhD is a senior biopharmaceutical executive with vast experience in the development of drugs from first in-human studies to approval and commercialization. Most recently, Dr. Gordon served as Vice President of Oncology Development at AbbVie Inc. (NYSE: ABBV), where he advanced the organization’s oncology pipeline through the FDA approval of venetoclax, obtained four Break Through Designations and several Orphan Drug Designations. Prior to AbbVie, Dr. Gordon held a position at Abbott Laboratories (NYSE: ABT) as Divisional Vice President of Global Oncology Development, where he advanced numerous compounds from Phase 0 through Phase 3 and developed partnerships to support programs, as well as at Ovation Pharmaceuticals Inc. as Chief Scientific Officer and Vice President of Clinical Affairs. Dr. Gordon earned his B.S. at State University of New York at Stony Brook and his Ph.D. and M.D. from The Johns Hopkins University School of Medicine where he was also an Assistant Professor of Oncology.

Phillip Low, PhD

SAB member

Phillip Low, PhD

SAB member


Dr. Philip S. Low is the Director of the Purdue Center for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry. Dr. Low has spent over 39 years 1) exploring novel methods of targeted drug development, and 2) characterizing the structure and function of the human erythrocyte membrane. During this period, he has published over 350 scientific articles in refereed journals and has over 50 US patents/patents pending (and many foreign patents). His drug delivery research has focused on the design and synthesis of targeting ligands that have proven successful in the targeted delivery of therapeutic and imaging agents to both cancer cells and aberrant immune cells involved in inflammatory and autoimmune diseases. Eight drugs stemming from this research are currently undergoing human clinical trials and three companies (Endocyte Inc., OnTarget Laboratories Inc., and HuLow Inc.) have been founded to commercialize these discoveries. Dr. Low has received an NIH MERIT Award, the ACS Award for Cancer Research (Sosnovsky Award), AACR Award for Outstanding Achievement in Chemistry in Cancer Research, both of Purdue’s awards for outstanding research, the University’s highest career achievement award (Morrill Award), and numerous other National and International awards, including election to the National Academy of Inventors. Dr. Low received his B.S. in Chemistry from Brigham Young University in 1971and his Ph.D. in Biochemistry from the University of California, San Diego in 1975.

Investors

Sante
Sante

News

Contact Us

196 Boston Avenue, Suite 2500, Medford, MA 02155

If you want to learn more about us, contact us: careers@solutherapeutics.com